Clinical-stage biotechnology company Ohr Pharmaceutical, Inc., has reportedly enrolled the first patient in its first Phase III clinical trial for lead drug candidate squalamine lactate ophthalmic solution, 0.2% (“Squalamine”, also known as OHR-102), for the treatment of neovascular age-related macular degeneration (wet AMD).
According to Ohr, they have a target enrollment of 650 treatment naïve subjects with wet AMD for the first of two randomized, double-masked, placebo-controlled trials. The primary endpoint for the Phase III trial will be a measurement of visual acuity at nine months, with subjects then followed for two years for safety.
Click here to read the full press release.
Source: Ohr Pharmaceutical, Inc.